Galway Shannon, Adatia Falisha, Grubisic Maja, Lee May, Daniele Patrick, Humphries Karin H, Sedlak Tara L
1 Department of Medicine, Vancouver General Hospital , Vancouver, Canada .
2 University of British Columbia , Vancouver, Canada .
J Womens Health (Larchmt). 2017 Sep;26(9):976-983. doi: 10.1089/jwh.2016.5983. Epub 2017 Apr 6.
Treatment of patients with stable angina and nonobstructive coronary artery disease (CAD) has not been well characterized. We comparatively evaluated medication use in males and females with stable angina with no CAD, nonobstructive CAD, and obstructive CAD.
We studied all patients ≥20 years old with stable angina undergoing coronary angiography in British Columbia (BC), Canada, from January 2008 to March 2010 (n = 7,535). No CAD, nonobstructive CAD, and obstructive CAD were defined as 0%, 1%-49%, and ≥50% luminal narrowing in any epicardial coronary artery, respectively. Medication use, 3 months before and 3 months following angiography, was obtained through BC PharmaNet for angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), beta-blockers, statins, antiplatelet agents, and prescriptions for all three ACE-I/ARBs, beta-blockers, and statins (combination therapy).
Following angiography, patients with no and nonobstructive CAD had significantly lower rates of prescription use of all medications, including combination therapy, than patients with obstructive CAD (p < 0.001). Use of ACE-I/ARBs, beta-blockers, statins, and combination therapy did not differ by sex, but females had higher use of CCB in all CAD groups, and clopidogrel in nonobstructive and obstructive CAD groups, compared to males.
In patients with stable angina, medication use following angiography is low in nonobstructive CAD with only 58.9% prescribed a statin and 19.4% on combination therapy at 3 months. There are no important sex differences in medication use in any CAD category post-angiography. Future studies should explore methods of improving quality of care in patients with nonobstructive CAD.
稳定型心绞痛和非阻塞性冠状动脉疾病(CAD)患者的治疗尚未得到充分描述。我们比较评估了患有稳定型心绞痛且无CAD、非阻塞性CAD和阻塞性CAD的男性和女性的药物使用情况。
我们研究了2008年1月至2010年3月在加拿大不列颠哥伦比亚省(BC)接受冠状动脉造影的所有≥20岁的稳定型心绞痛患者(n = 7535)。无CAD、非阻塞性CAD和阻塞性CAD分别定义为任何心外膜冠状动脉管腔狭窄0%、1%-49%和≥50%。通过BC PharmaNet获取血管造影前3个月和血管造影后3个月的药物使用情况,包括血管紧张素转换酶抑制剂(ACE-I)、血管紧张素受体阻滞剂(ARB)、钙通道阻滞剂(CCB)、β受体阻滞剂、他汀类药物、抗血小板药物,以及所有三种ACE-I/ARB、β受体阻滞剂和他汀类药物的联合治疗处方。
血管造影后,无CAD和非阻塞性CAD患者的所有药物(包括联合治疗)处方使用率显著低于阻塞性CAD患者(p < 0.001)。ACE-I/ARB、β受体阻滞剂、他汀类药物和联合治疗的使用在性别上无差异,但与男性相比,女性在所有CAD组中CCB的使用率更高,在非阻塞性和阻塞性CAD组中氯吡格雷的使用率更高。
在稳定型心绞痛患者中,非阻塞性CAD血管造影后的药物使用率较低,3个月时仅58.9%的患者服用他汀类药物,19.4%的患者接受联合治疗。血管造影后任何CAD类别中药物使用在性别上无重要差异。未来研究应探索改善非阻塞性CAD患者护理质量的方法。